a UCL Cancer Institute , London , United Kingdom.
b UCLH , London , United Kingdom.
Hum Vaccin Immunother. 2019;15(3):594-602. doi: 10.1080/21645515.2018.1540828. Epub 2018 Nov 20.
Blinatumomab (Blincyto, Amgen), a bi-specific antibody, is a first-in-class, targeted immunotherapy agent for treatment of B-cell malignancies with a novel mechanism of action which involves in-vivo engagement of the patient's T cells with CD19-expressing tumour cells. Clinical trials have demonstrated its efficacy in relapsed B-cell Acute Lymphoblastic Leukaemia (B-ALL) and B-cell Non-Hodgkin's Lymphoma including in patients who are refractory to chemotherapy. This review summarises the development and design of Blinatumomab, the outcome of clinical studies demonstrating its efficacy and how to manage the administration, practically, including relevant toxicities. We compare and contrast it to other emerging agents for treatment of B-cell malignancies.
Blinatumomab（blinatumomab，Amgen）是一种双特异性抗体，是一种首创的靶向免疫疗法药物，用于治疗 B 细胞恶性肿瘤，具有新颖的作用机制，涉及体内患者的 T 细胞与表达 CD19 的肿瘤细胞结合。临床试验已经证明了其在复发性 B 细胞急性淋巴细胞白血病（B-ALL）和 B 细胞非霍奇金淋巴瘤中的疗效，包括对化疗耐药的患者。本文综述了blinatumomab 的开发和设计，以及临床研究结果表明其疗效的情况，并介绍了如何在实践中管理该药的应用，包括相关毒性。我们将其与其他治疗 B 细胞恶性肿瘤的新兴药物进行了比较和对比。
